CD274 and cancer: Next, the evidence for pembrolizumab is the KEYNOTE-048 study, which examined the expression level of PD-L1 in tumor tissues and showed that it is effective to use other anti-cancer agents in combination depending on the amount of PD-L1 expression [4].